CLENBUTEROL POLICY – EFFECTIVE February 18, 2016

The Pennsylvania Harness Racing Commission ("Commission") is established to maintain a level of integrity and balanced playing field among those participating. In addition, the Commission understands that the medication Clenbuterol can be helpful to treat a horse for respiratory disease. The Commission also recognizes that the Standardbred horse races more frequently than the Thoroughbred horse.

Therefore, the following policy involving the use of the medication Clenbuterol is hereby established:

1. If the Standardbred horse has not raced within 10 days, Clenbuterol must not be detected in the plasma sample.

AND/OR

2. Must not be above a threshold of 140 picograms/mL in a urine sample.

3. If the Standardbred horse has raced within 10 days, has received clenbuterol under the direction of a veterinarian, and was tested for clenbuterol in the most recent race by a comparable drug testing program, the trainer can request the Commission to consider an alternate threshold of 800 picograms/mL in urine, provided the following actions are taken.

   A. Following the entry of the horse into race, the trainer is responsible for contacting the Commission field office where the horse has been entered to race and must inform the Commission that his/her horse has received Clenbuterol. Should a horse be drawn in as an "also eligible", the trainer of the horse should not have Clenbuterol administered or have any additional Clenbuterol until such time that the horse has been determined that the horse will not be needed in the race and released from the commitment by the judges and/or race secretary.

   B. Any treatment logs pertaining to a veterinarian administering and/or prescribing the medication Clenbuterol to a horse must be on file at the Commission office where the horse is entered into race at the time of entry. These reports must include information including, but not limited to: name of horse, tattoo number of the horse, trainer of the horse, dates of treatment, prescribed dosage, method of treatment and the time of the last treatment of clenbuterol given to the horse. This information must be provided to the Commission office on the veterinarian's letterhead or a Commission-supplied form. Trainer must also acknowledge that the Commission may take action against his/her license for failure to follow these established guidelines.

Failure to follow the above Commission adopted and approved guidelines may result in a positive test.

This policy will apply to all pari-mutuel and non-pari-mutuel racing events under the Commission's authority and jurisdiction.

During the February monthly harness racing commission meeting the attached policy was adopted pertaining to the medication clenbuterol. The adoption of this policy will be interpreted as it relates to the start of racing at each racing facility. The Meadows implementation of this policy will begin today, February 22, 2016 and therefore for the next 30 days warnings will be issued to any findings of clenbuterol as specified in the adopted policy. Pocono Downs implementation of this policy will begin on March 18, 2016 and the next 30 days warnings will be issued to any finding of clenbuterol as specified in the adopted policy and finally
Harrah’s Philadelphia will implement this policy on April 1, 2016 and for the next 30 days warnings will be issued surrounding any findings of clenbuterol as identified in the adopted policy.

HOWEVER, if a trainer has started a horse at a racetrack where this policy has already been implemented he will be held responsible by the date where he originally started his horse and not by the date of the start of racing at the racetrack where the findings were discovered.

George Crawford, Executive Secretary